ClinicalTrials.gg
RecruitingNCT04206852Updated Nov 12, 2026

Safety and Efficacy of Balloon Pulmonary Angioplasty in China

An observational study in Chronic Thromboembolic Pulmonary Hypertension, Takayasu Arteritis and Takayasu Arteritis With Pulmonary Artery Involvement, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational

How we know

From the registry’s dates

  • Started May 2018; still recruiting 8 years 6 months later.
Updated Nov 12, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Takayasu Arteritis with a site in China — 15 open to participants now, 16 under way, 2 of them phase 3. Takayasu Arteritis · China.

Planned enrollment
3rd of 11
2,000 · median 1,000
Started
2018
the only one that year
Observational
11 of 26
7 open now
Primary completion
2065-05
later than 15 of 15 live
Registered
10th of 26
by date
Lead sponsor
2 of 26
Chinese Pulmonary Vascular Disease Research Group

Among the 26 studies in Takayasu Arteritis with a site in China, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2018, is one of 11 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 10th registered.

Takayasu Arteritis

79 studies on the registry are indexed under Takayasu Arteritis; 33 are open to participants now.

Browse Takayasu Arteritis studies →

Open to participants now

15 of the 26 studies in Takayasu Arteritis with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Takayasu Arteritis studies recruiting now, 13 (52%) set no upper age limit and 10 (40%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Takayasu Arteritis with a site in China, or all of them as a file.
02

Study summary

Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.

The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.

Read the detailed description

This study is a prospective, multi-center, long-term observational project to study the safety and efficacy of BPA. Clinical evaluation, including: functional capacity, 6-minutes walking test, biomarkers, cardiopulmonary exercise test, electrocardiography, echocardiography, haemodynamics, pulmonary angiography and lung scintigraphy was performed before the initiation therapy of BPA, and 3-12 months after last session of BPA.

we also aim to evaluate the value of FAPI in predicting the efficacy and the prognosis of patients with CTEPH who received BPA.

03

Conditions studied

  • Chronic Thromboembolic Pulmonary Hypertension
  • Takayasu Arteritis
  • Takayasu Arteritis With Pulmonary Artery Involvement
  • Mediastinitis
  • Pulmonary Artery Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chronic thromboembolic pulmonary hypertension patients admitted in hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP \< 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
  2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
  3. Not amenable to pulmonary endarterectomy
  4. Willing to provide

Exclusion criteria

Exclusion Criteria:

  1. Patients unwilling or unable to provide written consent for participation in the study.
  2. Impossible to follow up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes

Interventions

  • ProcedureBalloon pulmonary angioplasty

    Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.

    Also known as: BPA

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events of BPA procedure.

    Surveillance of complications including: vessel injury, desaturation, cough, mild hemoptysis (\<50ml), severe hemoptysis (\>50ml), reperfusion pulmonary injury, death.

    Time frame: From initiation of BPA to 3-12 months after last session

  2. Change of Pulmonary artery pressure in mmHg caused by series of BPA.

    Pulmonary artery pressure in mmHg is obtained by right cardiac catheterization.

    Time frame: From initiation of BPA to 3-12 months after last session

  3. Change of Pulmonary vascular resistance (PVR) in Wood U caused by series of BPA.

    Pulmonary vascular resistance (PVR) in Wood U is obtained by right cardiac catheterization.

    Time frame: From initiation of BPA to 3-12 months after last session

  4. Change of cardiac index (CI) in L/m^2 caused by series of BPA.

    Cardiac index (CI) in L/m\^2 is obtained by right cardiac catheterization.

    Time frame: From initiation of BPA to 3-12 months after last session

  5. Change of World Health Organization (WHO) functional capacity classification caused by series of BPA.

    World Health Organization is obtained from electronic medical records.

    Time frame: From initiation of BPA to 3-12 months after last session

  6. Change of six minutes walk distance in meter caused by series of BPA.

    World Health Organization is obtained from electronic medical records.

    Time frame: From initiation of BPA to 3-12 months after last session

  7. Change of N-terminal B-type natriuretic peptide in pg/ml caused by series of BPA.

    World Health Organization is obtained from electronic medical records.

    Time frame: From initiation of BPA to 3-12 months after last session

  8. Change of Peak VO2/kg in ml/min/kg caused by series of BPA.

    Peak VO2/kg in ml/min/kg is obtained by cardiopulmonary exercise test.

    Time frame: From initiation of BPA to 3-12 months after last session

  9. Change of diffusing capacity for carbon monoxide caused by series of BPA.

    diffusing capacity for carbon monoxide in % is obtained from pulmonary function test

    Time frame: From initiation of BPA to 3-12 months after last session

  10. Change of fibroblast activation protein inhibitor expression after BPA

    Change of fibroblast activation protein inhibitor expression after BPA

    Time frame: From initiation of BPA to 3-12 months after last session

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2018 (actual). Primary completion is estimated for May 2065, 564 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2019
First posted
Dec 20, 2019
StartActual
May 11, 2018
Primary completionEst.
May 11, 2065
CompletionEst.
May 11, 2065
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
1000→2000
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrollment 1000→2000
    + 3 other changes: verification date, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04206852
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
Responsible party
Sponsor
First posted
Dec 20, 2019
Start date
May 11, 2018
Primary completion
May 11, 2065 (estimated)
Completion
May 11, 2065 (estimated)
Last update
Nov 12, 2026

Study contacts

Zhihong Liu, doctor
Contact
zhihongliufuwai@163.com
8601088396985

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion